Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) has received official minutes from a Type C meeting with the U.S. Food and Drug Administration (FDA) that support the company's plans for an adaptive Phase 2 field study of TNX-4800, its long-acting anti-OspA monoclonal antibody candidate designed to prevent Lyme disease. The announcement marks a significant step forward in the development of a preventative treatment for a tick-borne illness that affects hundreds of thousands of people in the United States each year.
The planned study is a randomized, placebo-controlled trial expected to enroll approximately 3,300 adults over two Lyme disease seasons. The primary objective is to evaluate the efficacy of TNX-4800 in preventing Lyme disease through six months after dosing. Manufacturing of the investigational product is on track for delivery to study sites in the first quarter of 2027, according to the company.
TNX-4800 is being developed as a seasonal immunopreventative, administered as two subcutaneous injections three months apart. This regimen is designed to provide protection throughout the U.S. Lyme disease season, which typically runs from spring through early fall. If successful, TNX-4800 could offer a much-needed option for individuals at high risk of exposure to infected ticks.
The FDA's feedback is a critical milestone for Tonix as it advances TNX-4800 through clinical development. A Type C meeting allows for a formal exchange of information between the FDA and a sponsor, and the supportive minutes indicate alignment on the study design and regulatory pathway. This de-risks the program and provides clarity for the company as it moves forward.
Lyme disease is the most common vector-borne illness in the United States, with an estimated 476,000 cases diagnosed annually, according to the Centers for Disease Control and Prevention. Current prevention strategies focus on personal protective measures and environmental management, but there is no vaccine available for humans. TNX-4800, if approved, would be a significant addition to Lyme disease prevention tools.
Tonix Pharmaceuticals is a fully-integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical need. The company's flagship medicine, TONMYA™ (cyclobenzaprine HCl sublingual tablets 2.8mg), was recently approved for fibromyalgia, marking the first new treatment for the condition in over 15 years. Tonix's CNS commercial infrastructure also supports its acute migraine products, Zembrace® SymTouch® and Tosymra®.
Beyond TNX-4800, Tonix is advancing a pipeline of immunology programs, including TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection. The company is also exploring the potential of TONMYA in Phase 2 clinical trials for major depressive disorder and acute stress disorder, as well as TNX-2900, which is Phase 2 ready for the treatment of Prader-Willi syndrome, a rare disease.
For more information on Tonix Pharmaceuticals and its pipeline, visit the company's newsroom at https://ibn.fm/TNXP.
